Brain Injury Traumatic Diffuse With Loss of Consciousness
Conditions
Keywords
Traumatic brain injury, Cerebral hemorrhage, hormone, trauma
Brief summary
Our understanding of neurosecretory dysfunction after TBI is still insufficient, and the number of patients with neuroendocrine dysfunction caused by craniocerebral trauma may be underestimated, especially the neuroendocrine changes related to HPA axis in the early stage after craniocerebral trauma. Moreover, there are few and fragmentary literature data on the benefits of hormone replacement therapy in patients with neuroendocrine disorders after traumatic brain injury. This requires more studies to further determine the characteristics of pituitary function or hormone disorders in the early stage after traumatic brain injury, which makes it necessary for us to further study the neuroendocrine dysfunction (hormone disorder) in the early stage after craniocerebral injury. To explore the relationship between craniocerebral injury and early hormone disorder by measuring the changes of early hormone levels in patients with TBI is of great significance for the early detection of related complications after craniocerebral injury and the evaluation of the prognosis of patients with craniocerebral injury, and can provide a new diagnosis and treatment plan for early intervention of related complications after TBI.
Interventions
PROCEDUREtrauma
The main purpose of this study is to observe whether the early hormone changes and trends in the two groups of patients with or without trauma.
Sponsors
General Hospital of Ningxia Medical University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years old. 2. The patient was clearly diagnosed as craniocerebral injury. 3. The Glasgow score on admission was 3-12 (moderate and severe). 4. It has complete preclinical data.
Exclusion criteria
1. Complicated with other severe visceral injuries or severe systemic fractures. 2. Suffered from craniocerebral tumors, endocrine diseases, cardiovascular diseases, depression, sleep and mental disorders. 3. In the past month, there are people who receive immune and hormone therapy. 4. Women during pregnancy and lactation. 5. Where there is a logical or common sense error in the data entered. 6. The lack of too much clinical data related to this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of GH | 1st, 7th and 14th day. | The levels of related hormones (growth hormone) were measured in patients with TBI. |
| Change of pituitary prolactin | 1st, 7th and 14th day. | The levels of related hormones (pituitary prolactin) were measured in patients with TBI. |
| Change of ACTH | 1st, 7th and 14th day. | The levels of related hormones ( ACTH) were measured in patients with TBI. |
| Change of cortisol | 1st, 7th and 14th day. | The levels of related hormones (cortisol) were measured in patients with TBI. |
| Change of FSH | 1st, 7th and 14th day. | The levels of related hormones (FSH) were measured in patients with TBI. |
| Change of thyroid hormone | 1st, 7th and 14th day. | The levels of related hormones (thyroid hormone) were measured in patients with TBI. |
Countries
China
Contacts
Primary ContactZhanfeng Niu, Doctor
Outcome results
None listed